6 posts on this topic, sorted most recent first.
Three drugs are about to change the GLP-1 conversation again. Orforglipron just got FDA approval. CagriSema is in phase 3 readouts. MariTide is the longer-tail bet. Here's the honest read on which deserves your patience and which is hype.
Eli Lilly launched Mounjaro in NZ February 2026 via Medsafe approval; private telehealth (Well Revolution + Pocket Lab) stocking from launch week. Wegovy still pending Medsafe filing. Foundayo (orforglipron) MHRA / EMA / Medsafe trajectory all 12-18 months behind FDA. What NZ readers can do today.
MOH Circular 87/2024 hit its one-year anniversary in March; the in-person-consultation rule is now observable, not theoretical. Foundayo (orforglipron) HSA pathway tracking 12-18 months behind FDA. Oral Wegovy 25mg HSA filing the more imminent question. What changed for SG readers since the April buyer's guide.
What changed for UK GLP-1 access since the April 2026 buyer's guide. NHS QOF tirzepatide indicators went live April 1; Cohort 2 (BMI 35-39.9) starts June; oral Wegovy 25mg shipped at private pharmacies in January; Foundayo (orforglipron) MHRA pathway tracked. Private market still dominant. What to do today.
What actually shifted in the last 60 days: Foundayo (orforglipron) approved early under the National Priority Voucher, oral Wegovy 25mg shipping, FDA proposes excluding tirzepatide from 503B bulks, RFK pulled 14 peptides off Category 2, survodutide phase 3 obesity readout. Routing impact for each.
Retatrutide, orforglipron, CagriSema, survodutide, MariTide, pemvidutide. Where each one sits in phase 3, the readout window, the mechanism, and what each approval would shift for routing decisions today. Bleeding edge of the science, conservative on the rating.